Organoid drug sensitivity-guided treatment

Preclinical

TTianjin Medical University Second Hospital

Organoid drug sensitivity-guided treatment is one of 4 therapeutic programs targeting Refractory Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Refractory TumorRecruiting

Refractory TumorPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Refractory Tumor

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

1 2

Opdivo

Bristol-Myers Squibb

Phase 1

1 3

Libtayo

Regeneron

Phase 1

1 4

Organoid drug sensitivity-guided treatment

TTianjin Medical University Second Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Refractory Tumor

NCT07906301

Clinical

Trials by Indication[1]

Refractory Tumor1 trial

A Multicenter, Multi-Arm, Exploratory Platform Clinical Study on the Therapeutic Efficacy of Organoid Drug Sensitivity-Guided Treatment in Patients With Refractory Tumors

Recruiting·TTianjin Medical University Second Hospital·Preclinical·NCT07906301·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Organoid drug sensitivity-guided treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Organoid drug sensitivity-guided treatment. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tianjin Medical University Second Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: TTianjin Medical University Second Hospital

Organoid drug sensitivity-guided treatment

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Refractory Tumor1 trial

References

Drug Info

Quick Facts

Related News